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Abstract
Background: To evaluate the objective and subjective long term swallowing function, and to relate dysphagia to
the radiation dose delivered to the critical anatomical structures in head and neck cancer patients treated with
intensity modulated radiation therapy (IMRT, +/- chemotherapy), using a midline protection contour (below hyoid,
~level of vertebra 2/3).
Methods: 82 patients with stage III/IV squamous cell carcinoma of the larynx, oropharynx, or hypopharynx, who
underwent successful definitive (n = 63, mean dose 68.9Gy) or postoperative (n = 19, mean dose 64.2Gy)
simultaneous integrated boost (SIB) -IMRT either alone or in combination with chemotherapy (85%) with curative
intent between January 2002 and November 2005, were evaluated retrospectively. 13/63 definitively irradiated
patients (21%) presented with a total gross tumor volume (tGTV) >70cc (82-173cc; mean 106cc). In all patients, a
laryngo-pharyngeal midline sparing contour outside of the PTV was drawn. Dysphagia was graded according
subjective patient-reported and objective observer-assessed instruments. All patients were re-assessed 12 months
later. Dose distribution to the swallowing structures was calculated.
Results: At the re-assessment, 32-month mean post treatment follow-up (range 16-60), grade 3/4 objective toxicity
was assessed in 10%. At the 32-month evaluation as well as at the last follow up assessment mean 50 months
(16-85) post-treatment, persisting swallowing dysfunction grade 3 was subjectively and objectively observed in
1 patient (1%). The 5-year local control rate of the cohort was 75%; no medial marginal failures were observed.
Conclusions: Our results show that sparing the swallowing structures by IMRT seems effective and relatively safe
in terms of avoidance of persistent grade 3/4 late dysphagia and local disease control.
Background
Limited data are available on the long term swallowing
function in intensity modulated radiotherapy (IMRT)
treated patients at risk for dysphagia [1-3].
We aimed to evaluate the objective and subjective long
term swallowing function, and to relate dysphagia to the
radiation dose delivered to the critical anatomical struc-
tures in our consecutively IMRT (+/- chemotherapy)
treated head and neck cancer patients.
We focused on serious subjective as well as objective
symptoms (grade 3/4 late effects).
Methods
Patient, disease and staging characteristics
A total of 82 out of 96 eligible patients ‘at risk’ for dys-
phagia due to a stage III/IV squamous cell carcinoma of
the larynx, oropharynx or hypopharynx agreed to parti-
cipate in our retrospective assessment. All included
patients were successfully treated with curative intent by
simultaneous integrated boost (SIB)-IMRT either alone
or in combination with chemotherapy or surgery at our
department between January 2002 and November 2005.
Seventy patients (85%) received concurrent cisplatin
chemotherapy (40mg/m2 i. v. weekly).
Exclusion criteria included loco-regional recurrence
at the time of assessment of swallowing dysfunction, a
f o l l o w - u pp e r i o d< 4m o n t h sa tt h ef i r s ta s s e s s m e n t ,
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omy, and loco-regional tumor stage ≤T1/2 N0.
Analysis has been performed after institutional
research ethics board approval. First, EORTC question-
naires regarding quality-of-life (QOL) and SOMA LENT
scale regarding late toxicity accompanied with an
informed consent form were mailed out to the patients,
who were already informed by phone. The subjective
answers resulted from a first assessment (mean 20
m o n t h s ;r a n g e :4 - 4 0m o n t h s ) , based on a questionnaire
for each patient. All patients -with special consideration
to those presenting with late toxicity > grade 2- have
been re-assessed objectively one year later (mean 32
months, range 16-60). The 5 year local disease control
and dysphagia grade 3/4 rates were based on the most
recent follow up assessment (’last time seen’).
Included in this analysis were 19 consecutive eligible
patients treated in the indicated time period, who
underwent surgery (without tracheostomy or laryngect-
omy) followed by postoperative IMRT, as the postopera-
tive set up was considered similarly ‘risky’ for the
development of late term dysphagia (fibrosis, edema),
and of additional informative value.
In addition, one interesting case of a patient who
underwent contra-lateral cobalt irradiation 30 years ago
was also included. This patient with a T3N2b lateral
oropharynx cancer experienced grade 4 dysphagia at the
subjective assessment. She received total IMRT dose of
69.6Gy unilaterally (daily dose: 2.11Gy) and 5 cycles of
concurrent cisplatin, after having been irradiated 30
years ago to the contra-lateral neck and tonsil with a
total dose of 60Gy by a Co
60; the cumulative dose
received by the swallowing structures could not be esti-
mated. Esophagus dilatations achieved temporary results;
however, although she remains PEG dependent, she is
able to swallow her saliva, and remained disease free at
the 4-year follow-up visit.
All patients were staged using the 2002 American
Joint Committee on Cancer (AJCC) criteria [4]. Patient
and disease characteristics are listed in Table 1. Mean
age of the cohort was 61 years (range 34-80). Volu-
metric staging is shown in Table 2.
Evaluation and scoring of late toxicity
Normal tissue effects were graded according to the
Radiation Therapy Oncology Group (RTOG)/European
Organization for Research and Treatment of Cancer
(EORTC) radiation morbidity scoring criteria [5].
Swallowing dysfunction and dysphagia were addition-
ally graded with subjective patient-reported and objec-
tive observer-assessed instruments. Patient-reported
clinical swallowing function was evaluated using the
“European Organization for Research and Treatment of
Cancer (EORTC) head-and-neck 35-item swallowing
and aspiration (QLQ-H&N35)” quality-of-life (QOL)
questionnaire.
Observer-assessed dysphagia was assessed according to
the SOMA LENT scale for head-and-neck carcinoma
radiotherapy objective criteria (German Version). During
the course of irradiation, all patients were clinically
assessed at regular weekly intervals, and 2 weeks to 2
months after completion of treatment. Four to 6 weeks
after completion of IMRT, all patients were also seen
regularly in our joint clinic at the Department of Head
and Neck Surgery. Institutional standards for patient
assessment included physical examination with addi-
tional flexible fiberoptic endoscopy at the Department of
Head and Neck Surgery approximately every 2 months
in the first year of follow-up, every 3 months in the sec-
ond to third year and every 6 months in the fourth to
fifth year.
Treatment characteristics
Patients were immobilized from head to shoulders with
commercially available thermoplastic masks in the
supine position. CT images (2 mm slice thickness) were
acquired from the top of the vertex to the level of the
carina with contrast agent infusion in non-operated
patients.
We used an extended-field IMRT (EF-IMRT) techni-
que, where the primary tumor was treated in one phase
along with the regional lymph nodes. Irradiation was
delivered with five or seven coplanar beam angles by a
Table 1 Patient and disease characteristics (n = 82)
Characteristics No of patients %
Gender
Male 68 83
Female 14 17
Primary site
Oropharynx central 26 32
Oropharynx lateral 29 35
Hypopharynx 18 22
Larynx 9 11
Stage III/IV 82 100
RT intention
primary 63 77
postoperative 19 23
Concomitant CT 70 85
≥4 cycles 63 77
previous RT 11
Abbreviations: No: number, RT: Radiotherapy. CT: Chemotherapy.
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Page 2 of 86-MV dynamic MLC system (sliding window technique)
(Varian Medical Systems, CA).
As previously described [1] an accelerated SIB- IMRT
t e c h n i q u ew a sp e r f o r m e dw i t had a i l yd o s eo f2 . 0 0 -
2.35Gy (total dose: 63-75Gy) to the primary tumor and
positive neck nodes in the definitive RT cases (n = 63)
and a daily dose of 1.80-2.00Gy to a total dose of 60-
66Gy in postoperative cases (n = 19). For intensity opti-
mization the prescribed dose should encompass at least
95% of the PTV. Additionally, no more than 20% of any
PTV would receive >110% of its prescribed dose, while
no more than 1% of any PTV would receive <93% of
the desired dose. The mean total treatment time was
45.3 days (32-55 days).
The protection of anatomical swallowing structures
was routinely performed by drawing a laryngo-pharyn-
geal midline ‘shielding’ contour outside the PTVs in all
cases. This sparing structure has been defined prospec-
tively in January 2002, when we implemented IMRT
clinically, and was provided to be used in all midline
areas where no PTV was required. This structure may
include esophageal, laryngeal, and pharyngeal structures.
Aimed dose constraint for this midline shielding was a
mean dose (Dmean) below 45Gy (Figure 1).
In oropharyngeal cancer patients, this structure was
usually contoured from the level of the hyoid (below the
lateral retropharyngeal lymph nodes, corresponding ~to
the cervical vertebra 2/3, Figure 1) to the lowest level at
which PTVs were drawn. In hypopharyngeal cancer
patients, midline protection is often limited to some
aspects of the larynx to just prevent laryngeal structures
from full tumor dose.
Clinical factors
The clinical variables examined for correlation with
grade 3-4 late toxicity included age, gender, primary
site, tumor stage, tumor volume, therapy sequence, addi-
tion of systemic therapy and IMRT treatment schedules.
Dosimetric factors
The dose distribution to the swallowing structures was
calculated on the original IMRT treatment plans. Based
Figure 1 Example: midline shielding as used according to our internal IMRT guidelines (pink contour, below hyoid/C3).
Table 2 Volumetric staging in patients treated with primary radiotherapy (n = 63)
total gross tumor volume (tGTV)
Primary site mean (range) 1-15cc 16-70cc >70cc
Oropharynx
base of tongue 34cc (9-127cc) 2 13 3
tonsil/lateral mesopharynx 51cc (4-171cc) 1 11 7
Larynx
Glottis 12cc (1-29cc) 1 1 0
Supraglottis 21cc (6-54cc) 2 5 0
Hypopharynx 46cc (5-173cc) 3 11 3
Total 44cc (1-173cc) 9 (14%) 41 (65%) 13 (21%)
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swallowing apparatus, the following anatomic structures
were retrospectively identified and delineated on the
axial CT-slices of each plan: the pharyngeal constrictor
muscles (PCs) - superior, middle and inferior-, the glot-
tic and supraglottic larynx (GSL) and the muscular com-
partment of the esophagus inlet (eim). In brief, the
superior constrictor muscle (scm) was defined from the
caudal tips of the pterygoid plates through the upper
edge of the hyoid bone, the middle constrictor muscle
(mcm) was defined from the upper through the lower
edge of the hyoid and the inferior constrictor muscle
(icm) was defined from below the hyoid through the
inferior edge of the cricoid. A structure named PCs was
outlined to involve the constrictors as a single structure.
The larynx (GSL) was contoured from the tip of the epi-
glottis superiorly to the bottom of the cricoid inferiorly.
Caudal to the inferior border of the cricoid, the esopha-
g u s( e i m )w a sc o n t o u r e d ,w i t hi t sc a u d a l - m o s te x t e n t
corresponding to the caudal-most extent of the low
neck target volumes. Dose-volume histograms to the
swallowing structures were assessed and mean dose,
maximum point dose (Dmax), minimum point dose
(Dmin), V30 (volume of a structure receiving >30Gy),
V50 (volume of a structure receiving >50Gy), V60
(volume of a structure receiving >60Gy), V65 (volume of
a structure receiving >65Gy), V70 (volume of a structure
receiving >70Gy), D50 (dose received by 50% volume of
a structure/median dose) and D80 (dose received by 80%
volume of a structure) were calculated.
Statistical analysis
Statistical calculations of Kaplan Meier curves were per-
formed using StatView
® program (Abacus Concepts
Inc., Berkeley, CA). A p value of ≤0.05 was considered
statistically significant.
Results
Between January 2002 and November 2005, a total of 82
out of 96 eligible patients successfully treated with SIB-
IMRT agreed to participate in our study. 80 patients
responded to all given questionnaires; 2/82 patients
declined to return the questionnaires, however, agreed
to allow using their objective data as assessable from
regular follow up visits. One previously irradiated
patient was excluded from the dysphagia analysis.
Late toxicity
At the first post-treatment follow-up (mean 20 month,
range 4-48), any subjective grade 3/4 toxicity (G3/4) was
reported by 14/80 patients (18%), while 66/80 patients
(82%) experienced grade 0-2 toxicity. At the second follow
up (objective assessment), grade 3/4 toxicity rate was 10%
(8/78) (two patients excluded because of tumor recur-
rence, two patients lost to follow-up); Table 3 shows sub-
jective and objective late toxicity. The mean dose and dose
range in definitively irradiated versus postoperatively irra-
diated patients is indicated in Table 1.
Prevalence of long term dysphagia (re-irradiated patient
excluded)
At the patient reported first assessment (mean 20
months, range 4-40), 77/79 patients experienced dyspha-
gia grade 0-2; five patients (8%) experienced dysphagia
grade 2, symptom that continued to persist only in one
patient by reevaluation (objective assessment, mean 32
months, range 16-60). Persistent dysphagia grade 3/4 was
found in one patient (1%). There were no cases of
Table 3 Frequency of grade 3/4 (G3/4) late toxicity at the subjective (mean 20 months; range 4-40) and objective
(mean 32 months; range 16-60) assessment
Grade 3/4 late term toxicity
Parameter S u b j e c t i v e O b j e c t i v e
Swallow pain 1n a
Dysphagia 2 (1 definitive/1postoperative) 2 (same pts. as subjective)
Taste alteration 9n a
Xerostomia 3 6
(same 3 pts as subjective + 3 others)
Weight loss ≥10% na 0
Hoarseness 0 0
Total No of pts 14/80 (18%) 8/78 (10%)
Abbreviations: na: not assessable, pts: patients, No: number
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quence of aspiration reported by patients or stated in the
patient charts (no radiological swallowing tests
performed).
At the second evaluation (mean 32 month post treat-
ment; n loco-regionally controlled patients with no pre-
vious radiation = 77) as well as at the most recent follow
up (“patient last seen”, mean 50 months, range 16-85,
Figure 2), persisting swallowing dysfunction grade (2-) 3
was subjectively and objectively assessed by 1 patient.
Weight loss/PEGs
Percutaneous endoscopic gastrostomy feeding tubes
(PEGs) were placed before or during treatment in 21 of
82 patients (26%). The mean time to PEG tube removal
was 8 months (range 5-25). At the time of the first ana-
lysis (20-month follow up), 6/21 patients (7% of all, ~1/3
of the PEG patients) were still using PEG for some or all
of their nutrition. Patients sustained median weight loss
of 5.1 kg (range 0-20 kg) during treatment, while one
year post treatment there was no patient who had lost
>10% of body weight. Only two of those 6 patients
remained PEG-dependent (10% of all PEG patients, 2% of
the entire cohort); the other 4 patients regained indepen-
dence of PEG 14, 16, 33 and 36 months after completion
of IMRT, respectively. In none of the patients who
remained loco-regionally disease free, a PEG had to be
placed during the monitored follow up period/replaced
once the PEG has been removed.
Swallowing structure doses
The median doses (median of the median dose) to the
swallowing structures, the partial volumes receiving spe-
cified doses (VD) in all patients and comparable results
of reported series are detailed in Tables 4 and 5.
Long term local control and overall survival
The 3 and 5 year local control rates of the assessed
cohort were 78 and 75% (Figure 2), the corresponding
overall survival rates were 80 and 77%, respectively
(Kaplan Meier survival curves, December 2010). None
of the local failures were found related to the midline
protection structure (all failures analysed: no medial
marginal failures).
Discussion
Recent gains in the management of head and neck can-
cer have been achieved due to concurrent chemo-radio-
therapy with altered fractionated three-dimensional
conformal radiotherapy (3D-CRT) or IMRT technique
[10-12]. The use of these high intensity treatments has
resulted in considerable rates of swallowing dysfunction,
both acute (15-63%) and long term (3-21%) [13-20].
C o m p r e h e n s i v ed a t ao nl a t et o x i c i t yf r o mr a n d o m i z e d
and nonrandomized trials, however, are sparse.
In our cohort of patients treated with SIB-IMRT
either alone or in combination with chemotherapy or
surgery, the rate of grade 3/4 long term dysphagia was
1%, comparable to that seen in other IMRT studies, and
considerably better than that observed in 3D-CRT stu-
dies (Table 6). These findings of a low rate of severe
dysphagia in a patient cohort at risk motivate efforts to
reduce the doses to the swallowing structures, fact
which could reduce the severity and prevalence of dys-
phagia. This may be reached by a simple protection
structure along the midline were no PTV is needed (Fig-
ure 1). Analysis of the relationship between the swallow-
ing structure doses and the development of late
dysphagia were limited due to the single event, pre-
cluded statistical significance. Median doses of the swal-
lowing structures in the own cohort were comparable to
reported series [7,21] (Table 4, 5). The limitation of our
study was the retrospective nature of the analysis,
whereas midline protection contouring (Figure 1) was
prospectively performed as part of our internal IMRT
guidelines. Similar to the parotid gland protection, no
oncological compromises are acceptable in contouring
the midline sparing structure. The group of Eisbruch et
al [2] suggested that the high loco-regional control rates
have not been compromised by the efforts to spare the
parts of the swallowing structures not involved by
tumor and not at risk of subclinical disease. In addition,
in a previous evaluation of our hypopharynx-larynx
patient cohort [22] treated with IMRT using midline
sparing as far as feasible, local failures were not found
related to the midline sparing structures.
The low percentage of PEG tube dependence (7%) at
the mean 20-month follow-up may be interpreted as a
surrogate of limited swallowing problems.
Published analyses focused on predicting the probabil-
ity of severe acute or late dysphagia during or after RT
[23,24] between patient-rated and objective assessment
of dysphagia are conflicting.
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Figure 2 5-year local control rate (75%) and rate of freedom of
grade 3/4 late dysphagia (re-irradiated patient excluded, 99%).
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Page 5 of 8Table 5 Partial volumes receiving specified doses (VD) to the swallowing structures in all patients and comparison to
the data as reported by Feng et al 2007 21
PCs, median (range) GSL, median (range) eim, median (range)
V50 (%) V60 (%) V65 (%) V70 (%) V50 (%) V60 (%) V65 (%) V70 (%) V50 (%) V60 (%) V65 (%)
Current study 88.5 (10-100) 43.9 (0-94) 29 (0-60) 7.3 (0-40) 3.9 (1-100) 21.1 (0-98) 8.9 (0-94) 0 (0-67) 5.1 (0-100) 0 (0-87) 0 (0-84)
Feng et al [21] 90 (58-100) 73 (36-100) 57 (20-99) NA 69 (1-100) 37 (0-100) 20 (0-100) NA 14 (0-100) 0 (0-100) 0 (0-78)
Abbreviations: PCs: pharyngeal constrictor muscles, GSL: glottic and supraglottic larynx, eim: muscular compartment of the esophagus inlet, NA: not assessed.
Table 6 Results from selected series regarding late toxicity in head and neck cancer patients treated with RT ±
chemotherapy
Technique Authors
[reference]
year No of
patients
median follow up
(months)
stage lll/lV
(%)
Chemotherapy
(%)
grade 3/4 late
toxicity
Chao et al [25] 2003 74 30 93 23 0
I
de Arruda et al [14] 2006 50 18 92 86 3 (6%)
M
Lee et al [17] 2006 41 31 100 100 5 (12%)
R
Studer et al [1] 2006 115 18 52 78 18 (15%)
T
present study 2010 81* 55 100 85 7 (9%)
Denis et al [26] 2003 44 60 100 61 30 (68%)
3D-CRT
Huguenin et al [19] 2004 224 39 97 50 G3: 92 (41%)
G4: 5 ("%)
Abbreviations: IMRT: Intensity modulated radiation therapy; 3D-CRT: three-dimensional conformal radiotherapy (*patient with previous Cobalt radiation therapy
excluded).
Table 4 Median doses (median of the median dose) to the swallowing structures in all patients and comparison to
reported series
Swallowing structures Current study Feng et al 2007 [21] Levendag et al* 2007 [7]
Median Range Median Range Median Range
PCs Volume (cc) 20 11-32 NA NA NA NA
Dose (Gy) 59 39-66 64 51-72 48 6.0-73.0
scm Volume (cc) 12 6-21 NA NA NA NA
Dose (Gy) 59.4 24-69 68 57-74 51 22.0-73.0
mcm Volume (cc) 3.6 1.5-9 NA NA NA NA
Dose (Gy) 59 37.0-71.5 64 53-75 48 11.0-72.0
icm Volume (cc) 3.7 0.9-7 NA NA NA NA
Dose (Gy) 53 29-73 51 30-70 32 6.0-73.0
GSL Volume (cc) 15.3 6.4-23 NA NA NA NA
Dose (Gy) 53 28-70 55 22-72 NA NA
eim Volume (cc) 5.4 0.7-44 NA NA NA NA
Dose (Gy) 39 16.0-67.8 44 15-66 18 3.0-64.0
*The results are not entirely comparable with the study of Levendag et al [7], as there is a difference in the delineation of muscular structures. In Levendag et al.
the anterior part of scm and mcm were not delineated and eim was defined as the proximal 1 cm of the esophageal inlet, regardless of the caudal-most extent
of the low neck target volumes.
Abbreviations: PCs: pharyngeal constrictor muscles, scm: superior constrictor muscle, mcm: middle constrictor muscle, icm: inferior constrictor muscle, GSL: glottic
and supraglottic larynx, eim: muscular compartment of the esophagus inlet, NA: not assessed
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in addition with the objective parameters ‘body weight’
and ‘dependency of a long term PEG’, are reliable
answer and were found congruent with the objective
grading. No specific tests were performed to detect
potentially aspiration-related, clinically not obvious
pneumonia.
Conclusions
In conclusion, IMRT using a midline contour to spare
swallowing structures outside PTVs is relatively safe and
effective in terms of local disease control and avoidance
of persistent late dysphagia. The subjective patients’ esti-
mation of late dysphagia was compatible with the objec-
tive assessment of swallowing dysfunction.
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